JP2023526232A5 - - Google Patents
Info
- Publication number
- JP2023526232A5 JP2023526232A5 JP2022568743A JP2022568743A JP2023526232A5 JP 2023526232 A5 JP2023526232 A5 JP 2023526232A5 JP 2022568743 A JP2022568743 A JP 2022568743A JP 2022568743 A JP2022568743 A JP 2022568743A JP 2023526232 A5 JP2023526232 A5 JP 2023526232A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- ctla
- sequence
- antibody
- activatable anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026042944A JP2026102780A (ja) | 2020-05-12 | 2026-03-17 | 活性化可能な抗ｃｔｌａ－４抗体の投薬および投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023850P | 2020-05-12 | 2020-05-12 | |
| US63/023,850 | 2020-05-12 | ||
| PCT/US2021/031670 WO2021231346A1 (en) | 2020-05-12 | 2021-05-11 | Dosing and administration of activatable anti-ctla-4 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026042944A Division JP2026102780A (ja) | 2020-05-12 | 2026-03-17 | 活性化可能な抗ｃｔｌａ－４抗体の投薬および投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023526232A JP2023526232A (ja) | 2023-06-21 |
| JP2023526232A5 true JP2023526232A5 (enExample) | 2024-05-20 |
Family
ID=76197648
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022568743A Pending JP2023526232A (ja) | 2020-05-12 | 2021-05-11 | 活性化可能な抗ｃｔｌａ－４抗体の投薬および投与 |
| JP2026042944A Pending JP2026102780A (ja) | 2020-05-12 | 2026-03-17 | 活性化可能な抗ｃｔｌａ－４抗体の投薬および投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026042944A Pending JP2026102780A (ja) | 2020-05-12 | 2026-03-17 | 活性化可能な抗ｃｔｌａ－４抗体の投薬および投与 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230192856A1 (enExample) |
| EP (1) | EP4149544A1 (enExample) |
| JP (2) | JP2023526232A (enExample) |
| KR (1) | KR20230009432A (enExample) |
| CN (1) | CN115515633A (enExample) |
| AR (1) | AR122043A1 (enExample) |
| AU (1) | AU2021270513A1 (enExample) |
| BR (1) | BR112022022713A2 (enExample) |
| CA (1) | CA3178649A1 (enExample) |
| IL (1) | IL298126A (enExample) |
| MX (1) | MX2022014113A (enExample) |
| TW (1) | TW202207982A (enExample) |
| WO (1) | WO2021231346A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260048119A1 (en) * | 2022-08-05 | 2026-02-19 | Bristol-Myers Squibb Company | Anti-ctla4 antibodies for treatment of kras mutant cancers |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100845354B1 (ko) * | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | 항－ｃｔｌａ－4 항체의 용도 |
| US8449886B2 (en) * | 2008-01-08 | 2013-05-28 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
| WO2010014784A2 (en) * | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010042433A1 (en) * | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| US9119129B2 (en) * | 2012-05-05 | 2015-08-25 | Broadcom Corporation | MAC header based traffic classification and methods for use therewith |
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| EP2912063A1 (en) * | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| SMT201900242T1 (it) * | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| EP3114144A1 (en) * | 2014-03-05 | 2017-01-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| WO2016100561A2 (en) * | 2014-12-16 | 2016-06-23 | Bristol-Myers Squibb Company | Use of immune checkpoint inhibitors in central nervous systems neoplasms |
| WO2016127052A1 (en) * | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
| US10196445B1 (en) * | 2015-03-17 | 2019-02-05 | Bristol-Myers Squibb Company | Ipilimumab variant with enhanced ADCC |
| HRP20201334T1 (hr) * | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| WO2016176503A1 (en) * | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| WO2016196389A1 (en) * | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| US11072657B2 (en) * | 2015-11-18 | 2021-07-27 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| EP3408296A1 (en) * | 2016-01-27 | 2018-12-05 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| WO2017210631A1 (en) * | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer |
| KR102976378B1 (ko) * | 2016-06-03 | 2026-06-11 | 브리스톨-마이어스 스큅 컴퍼니 | 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 |
| WO2018049042A1 (en) * | 2016-09-07 | 2018-03-15 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancers by inhibiting estrogen signaling in myeloid-derived suppressor cells |
| KR102634093B1 (ko) * | 2016-10-28 | 2024-02-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법 |
| CN110072890B (zh) * | 2016-11-03 | 2022-11-29 | 百时美施贵宝公司 | 可活化的抗ctla-4抗体及其用途 |
| IL307242B1 (en) * | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| JP2020522495A (ja) * | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
| WO2019036433A2 (en) * | 2017-08-16 | 2019-02-21 | Bristol-Myers Squibb Company | ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION |
| EP3694884A1 (en) * | 2017-10-15 | 2020-08-19 | Bristol-Myers Squibb Company | Methods of treating tumor |
| WO2019140150A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| EP3774911A1 (en) * | 2018-03-30 | 2021-02-17 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US11554120B2 (en) * | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| JP2022505647A (ja) * | 2018-10-23 | 2022-01-14 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍の処置方法 |
| MX2021005708A (es) * | 2018-11-16 | 2021-09-21 | Bristol Myers Squibb Co | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. |
| WO2020198676A1 (en) * | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| JP7720785B2 (ja) * | 2019-04-18 | 2025-08-08 | ブリストル－マイヤーズ スクイブ カンパニー | 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント |
| WO2021055994A1 (en) * | 2019-09-22 | 2021-03-25 | Bristol-Myers Squibb Company | Quantitative spatial profiling for lag-3 antagonist therapy |
| WO2021127554A1 (en) * | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
| CN115210235A (zh) * | 2020-01-27 | 2022-10-18 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| CN115151547A (zh) * | 2020-01-27 | 2022-10-04 | 百时美施贵宝公司 | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物 |
| KR20240153583A (ko) * | 2022-02-25 | 2024-10-23 | 브리스톨-마이어스 스큅 컴퍼니 | 결장직장암종에 대한 병용 요법 |
| CN122459678A (zh) * | 2023-12-29 | 2026-07-24 | 百时美施贵宝公司 | KRAS抑制剂与Treg耗竭剂的组合疗法 |
-
2021
- 2021-05-10 AR ARP210101266A patent/AR122043A1/es not_active Application Discontinuation
- 2021-05-11 MX MX2022014113A patent/MX2022014113A/es unknown
- 2021-05-11 US US17/998,521 patent/US20230192856A1/en active Pending
- 2021-05-11 EP EP21729172.3A patent/EP4149544A1/en active Pending
- 2021-05-11 CN CN202180033213.2A patent/CN115515633A/zh active Pending
- 2021-05-11 CA CA3178649A patent/CA3178649A1/en active Pending
- 2021-05-11 KR KR1020227042908A patent/KR20230009432A/ko active Pending
- 2021-05-11 IL IL298126A patent/IL298126A/en unknown
- 2021-05-11 JP JP2022568743A patent/JP2023526232A/ja active Pending
- 2021-05-11 WO PCT/US2021/031670 patent/WO2021231346A1/en not_active Ceased
- 2021-05-11 AU AU2021270513A patent/AU2021270513A1/en not_active Abandoned
- 2021-05-11 BR BR112022022713A patent/BR112022022713A2/pt not_active IP Right Cessation
- 2021-05-12 TW TW110117058A patent/TW202207982A/zh unknown
-
2026
- 2026-03-17 JP JP2026042944A patent/JP2026102780A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020147A5 (enExample) | ||
| Gbolahan et al. | A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma | |
| Tomek et al. | Chemotherapy for malignant pleural mesothelioma: past results and recent developments | |
| Haas et al. | Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies | |
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| JP2021513541A5 (enExample) | ||
| JP2019521087A5 (enExample) | ||
| NO20066056L (no) | Behandling med Gemcitabin og en EGFR-inhibitor | |
| JP2021510697A5 (enExample) | ||
| JP2024527109A5 (enExample) | ||
| Kondo et al. | A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact | |
| Lee et al. | S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer: results from the randomized phase III POST trial | |
| JP2025504278A5 (enExample) | ||
| JP2023524359A5 (enExample) | ||
| Fujiwara | Three ongoing intraperitoneal chemotherapy trials in ovarian cancer | |
| He et al. | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments | |
| JP2024519450A5 (enExample) | ||
| Morise et al. | Patient with advanced intrahepatic cholangiocarcinoma with long-term survival successfully treated with a combination of surgery and chemotherapy | |
| Lee et al. | 332 Novel TGF-β signatures in metastatic colorectal cancer patients treated with vactosertib in combination with pembrolizumab | |
| Aigner et al. | Carotid artery infusion via implantable catheters for squamous cell carcinoma of the tonsils | |
| Di Lauro et al. | Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma | |
| JPWO2022260132A5 (enExample) | ||
| Argenta et al. | Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up | |
| Crane et al. | A Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: RTOG PA0411 | |
| King | Nivolumab plus Ipilimumab Yields High Rate of pCR in the Neoadjuvant Setting for Patients with Resectable MSI/dMMR Oeso-Gastric Adenocarcinoma. |